Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cancer advanced colorectal

Gamelin E, Boisdron-Celle M, Guer-in-Meyer V et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999 17 1105-1110. [Pg.306]

Shields AF, Lange LM, Zalupski MM. Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. Am J Clin Oncol 2001 24 96. [Pg.47]

Fluorouracil (5-FU) is a major drug in the treatment of advanced colorectal cancer. Of the administered 5-FU, 70-80% is degraded by DPD in vivo to dihydrofluorouracil. [Pg.65]

Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G Macdonald J, Mehn S, Berg D, Brescia F, Hochster H, Cohn A. (2008) A phase II study of milataxel A novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol 61 453-458. [Pg.170]

Starling N, Cunningham D. Monoclonal antibodies against vascular endothehal growth factor and epidermal growth factor receptor in advanced colorectal cancers present and future directions. Curr Opin Oncol 2004 16 385-90. [Pg.83]

Gill S, Goldberg RM. Eirst-hne treatment strategies to improve survival in patients with advanced colorectal cancer. Drugs 2004 64 27-44. [Pg.84]

VX-680 (71) is the most advanced pyrazole class Aurora inhibitor, disclosed by Vertex. The compound is reportedly in Phase I clinical development in patients with relapsed or refractory acute myelogenous leukemia, myelodys-plastic syndrome, acute lymphocytic leukemia, and chronic myelogenous leukemia and in Phase II for advanced colorectal cancer [172,173]. VX 680 (71) was a potent inhibitor of all three Aurora kinase enzymes (Aurora-A Ki = 0.0006 p.M Aurora-B Ki = 0.018 p,M Aurora-C Ki = 0.0046 tiM). Com-... [Pg.256]

In combination with 5-fluorouracil (5-FU) to prolong survival in the palliative treatment of patients with advanced colorectal cancer. [Pg.65]

Advanced colorectal cancer Either of the following 2 regimens is recommended ... [Pg.65]

Abbruzzese JL, Pazdur R, Ajani J, et al. A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1991 10 456. [Pg.125]

Mani S, et al. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer Minimal activity in colorectal cancer. Invest New Drugs 1998 16 275. [Pg.125]

Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998 16( 1 ) 301—308. [Pg.234]

Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006 56 106-130. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000 18 2938-2947. [Pg.168]

Toumigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequenee in advanced colorectal cancer a randomized GERCOR study. JC// Oncol 2004 22 229-231. [Pg.168]

Cohen V, Panet-Raymond V, SabbaghianN et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003 9 1611-1615. [Pg.168]

Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer an updated meta-analysis. J Clin Oncol 2004 22 3766-3775. [Pg.168]

Mareuello E, Altes A, del Rio E et al. Single nucleotide polymorphism in the 5 tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004 112 733-737. [Pg.171]

Kopetz S, HofFPM. Cytotoxic chemotherapy for advanced colorectal cancer recent advances in management. Oncology (Williston Park) 2005 19 11-17. [Pg.258]

Irinotecan is an analogue of camptothecin, a topoisomerase I inhibitor that is used for the treatment of advanced colorectal cancer and a few other solid tumors. Irinotecan is first converted to an active metabolite, SN-38, which is further conjugated into the inactive SN-38 glucuronide (SN-38 G), mainly by UGTIAI, and then eliminated via the bile. A common dinucleotide (TA) repeat polymorphism (containing 5, 6, 7, or 8 copies of TA repeat) has been identified in the UGTIAI promoter TATA box. [Pg.355]

Park DJ, Stoehlmacher J, Zhang W et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001 61 8654-8658. [Pg.368]

Francis RJ, Sharma SK, Springer C, Green AJ, et al. 2002. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer. 87 600-607. [Pg.123]

Dragovich, T., Mendelson, D., Kurtin, S., Richardson, K., Von Floff, D., and Floos, A. (2006). A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother. Pharmacol., 58, 759-764. [Pg.410]

Aggarwal, S. and E. Chu. 2005. Current therapies for advanced colorectal cancer. Oncology (Williston. Park) 19 589—595. [Pg.327]

Punt CJ, Voest EE, Tueni E, et al. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. Br J Cancer 1997 76(10) 1376-1381. [Pg.426]

Lersch, C., Zeuner, M., Bauer, A., Siemens, M., Hart, R., Drescher, M., Fink, U., Dancygier, H., and Classen, M. 1992. Nonspecific immunostimulation with low doses of cyclophosphamide (LDCY), Thymnostimulin, Echinacea purpurea extracts (Echinacin ) in patients with far advanced colorectal cancers preliminary results. Cancer Investig. 10, 343-348. [Pg.169]

Case study level 2 - Treatment of advanced colorectal cancer... [Pg.173]

Case study level 1 - Non-small cell lung cancer 171 Case study level 2 - Treatment of advanced colorectal cancer 173 Case study level 3 - Treatment of metastatic breast cancer and its complications 175... [Pg.465]

Erbitux Cetuximab ImClone Systems 2/2004 Advanced colorectal cancer NS0... [Pg.1423]

See other pages where Cancer advanced colorectal is mentioned: [Pg.1348]    [Pg.304]    [Pg.162]    [Pg.446]    [Pg.66]    [Pg.361]    [Pg.97]    [Pg.121]    [Pg.724]    [Pg.726]    [Pg.616]    [Pg.356]    [Pg.1170]    [Pg.384]    [Pg.579]    [Pg.50]    [Pg.206]    [Pg.218]    [Pg.174]    [Pg.189]    [Pg.298]   
See also in sourсe #XX -- [ Pg.37 ]



SEARCH



Colorectal cancer

© 2024 chempedia.info